Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 13/20 | 0.69 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.69 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.69 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TMPRSS4 | Q9NRS4 | 6/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | IKBKB | O14920 | 1/20 | 0.52 |
| ▸ | CHUK | O15111 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MYLK | Q15746 | 1/20 | 0.52 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330274 | 0.82 | P2RX1 (1.00) | P2RX1P2RX7P2RX4P2RX3ALOX15 | |
| SCHEMBL4971446 | 0.80 | ALOX15 (0.67) | ALOX15NFKB1NFKB2RELAMEN1 | |
| SCHEMBL330224 | 0.80 | ALOX15 (0.60) | P2RX1P2RX7P2RX4ALOX15TMPRSS4 | |
| SCHEMBL18341196 | 0.79 | TRPV1 (0.48) | P2RX1P2RX7P2RX4P2RX3ALOX15 | |
| SCHEMBL14582008 | 0.77 | P2RX1 (0.61) | P2RX1P2RX7P2RX4P2RX3TMPRSS4 | |
| SCHEMBL3497353 | 0.77 | P2RX1 (0.72) | P2RX1P2RX7P2RX4P2RX3TMPRSS4 | |
| SCHEMBL14582469 | 0.77 | P2RX1 (0.62) | P2RX1P2RX7P2RX4P2RX3TMPRSS4 | |
| SCHEMBL13475222 | 0.76 | P2RX1 (0.59) | P2RX1ALOX15MEN1KMT2ARXFP1 | |
| SCHEMBL9407432 | 0.75 | FADS1 (0.58) | P2RX1P2RX7P2RX4ALOX15MEN1 | |
| SCHEMBL127962 | 0.75 | P2RX1 (1.00) | P2RX1P2RX7P2RX4P2RX3TMPRSS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1512397-B1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7626042-B2 | O-substituted hydroxyaryl derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | IL1A, TNF, NFKBIA | P2RX1 2507/4885P2RX7 2251/4885P2RX4 3900/4885 |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | RELA, NFKBIA, NFE2 | P2RX1 3644/4885P2RX7 3286/4885P2RX4 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.